Arrowhead Pharmaceuticals Secures US$400 Million Sixth Street Loan to Extend Debt Maturities to 2031
Arrowhead Pharmaceuticals has overhauled its debt structure through a new US$400 million term loan from Sixth Street, lowering its borrowing costs and pushing debt maturities out to 2031, simplywall.st reported. The transaction provides the biotechnology company with additional financial flexibility as its stock experiences a pullback from multi-year highs.
The financing agreement arrives during a volatile trading period for the company. Arrowhead Pharmaceuticals shares declined 34.47% over the preceding 90 days and dropped 15.27% year to date. Longer-term performance shows a 45.05% total shareholder return over the past year and a 114.81% return across three years, reflecting past product progress weighed against recent momentum cooling.
Pipeline Progress and Valuation Discrepancies Shape Market Outlook
The bullish case for the stock centers on Arrowhead’s advancing late-stage clinical pipeline, particularly the anticipated commercial launch of plozasiran for familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (SHTG). Late-stage clinical trials for three additional RNAi therapies targeting major unmet medical needs also support expectations for revenue acceleration as approvals materialize. The most followed market narrative places fair value for the stock at approximately $110 against a last close of $57.44, implying the company is undervalued by roughly 48% using a 7.6% discount rate.
Conversely, valuation metrics present a mixed picture. Arrowhead trades on a price-to-sales (P/S) ratio of 12.1x, compared to a 10.9x average for the broader United States biotech group and a 13x peer average, while the calculated fair P/S ratio sits higher at 15.7x. This dynamic leaves the thesis heavily dependent on plozasiran execution and partner funding, meaning any clinical trial setback or collaboration disruption could test current valuations.
Arrowhead Pharmaceuticals extends debt maturities to 2031
What is the primary use of the new US$400 million Sixth Street term loan?
The term loan cuts Arrowhead Pharmaceuticals’ borrowing costs and extends its debt maturities out to 2031 to create financial breathing room.
How does Arrowhead’s P/S ratio compare to industry peers?
Arrowhead trades on a price-to-sales ratio of 12.1x, which compares to a 10.9x average for the wider United States biotech group and a 13x peer average.
What are the key pipeline catalysts driving the valuation narrative?
The primary catalysts include the expected launch of plozasiran for familial chylomicronemia syndrome and severe hypertriglyceridemia, alongside late-stage trials for three other RNAi therapies.
Related reading